View ValuationMicroPort CardioFlow Medtech 향후 성장Future 기준 점검 5/6MicroPort CardioFlow Medtech (는) 각각 연간 104.9% 및 24.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 111.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 1.7% 로 예상됩니다.핵심 정보104.9%이익 성장률111.06%EPS 성장률Medical Equipment 이익 성장16.1%매출 성장률24.7%향후 자기자본이익률1.70%애널리스트 커버리지Low마지막 업데이트18 Dec 2024최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 31MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 04, 2026MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 04, 2026. Location: no.501 niudun road, pudong new district, shanghai, China공시 • Mar 18MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2025 Results on Mar 30, 2026MicroPort CardioFlow Medtech Corporation announced that they will report fiscal year 2025 results on Mar 30, 2026공시 • Aug 15MicroPort CardioFlow Medtech Corporation to Report First Half, 2025 Results on Aug 28, 2025MicroPort CardioFlow Medtech Corporation announced that they will report first half, 2025 results on Aug 28, 2025공시 • Jun 27MicroPort CardioFlow Medtech Corporation Announces Board Changes, Effective June 27, 2025MicroPort CardioFlow Medtech Corporation announced that Dr. Ding Jiandong (Dr. Ding) retired as an independent non-executive Director with effect from the conclusion of the AGM and did not offer himself for re-election at the AGM as disclosed in the Circular. Accordingly, Dr. Ding ceased to act as a member of each of the audit committee (the Audit Committee) and nomination committee of the Company (the Nomination Committee) with effect from the conclusion of the AGM. Dr. Ding has confirmed that he has no disagreement with the Board and there is no matter relating to his retirement that needs to be brought to the attention of the Shareholders or the Stock Exchange. The Board announced that Dr. Hu Bingshan (Dr. Hu) has been appointed as an independent non-executive Director and a member of each of the Audit Committee and Nomination Committee, with effect from June 27, 2025 following the retirement of Dr. Ding. The biographical details of Dr. Hu are set out: Dr. Hu, aged 43, has successively served as associate professor and professor at the University of Shanghai for Science and Technology since November 2016. His main research field is rehabilitation and nursing robotics. From October 2010 to November 2016, Dr. Hu worked as a space robotics systems engineer at the Shanghai Aerospace System Engineering Institute in the China Aerospace Science and Technology Corporation. In 2015, he also served as a visiting scholar at the University of Hamburg in Germany. Dr. Hu serves as a committee member for the Sports Health and Industry Promotion Committee of China Association of Rehabilitation Medicine and other relevant academic organizations. He received the First Prize and the Second Prize of Science and Technology from the China Association of Rehabilitation Medicine in October 2023 and in September 2024, respectively. Dr. Hu has published more than 50 papers in internationally recognized journals or academic conferences. He is also an inventor or co-inventor of more than 70 Chinese and overseas patents. Dr. Hu received his bachelor's degree in electrical engineering and automation and his master's degree in power electronics and electric drives from Harbin University of Science and Technology in July 2003 and April 2006, respectively, and obtained his Ph.D. in mechatronic engineering from Shanghai Jiao Tong University in December 2010. Dr. Hu shall only hold office until the next annual general meeting of the Company and will be eligible for and subject to re-election at such meeting in accordance with the articles of association of the Company.공시 • Mar 28MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 27, 2025MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 27, 2025. Location: no. 1661 zhangdong road, zhangjiang hi-tech park, pudong new district, shanghai China공시 • Mar 17MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2024 Results on Mar 27, 2025MicroPort CardioFlow Medtech Corporation announced that they will report fiscal year 2024 results at 4:00 PM, China Standard Time on Mar 27, 2025공시 • Aug 15MicroPort CardioFlow Medtech Corporation to Report First Half, 2024 Results on Aug 28, 2024MicroPort CardioFlow Medtech Corporation announced that they will report first half, 2024 results on Aug 28, 2024공시 • Mar 29MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024. Location: No. 1661 Zhangdong Road, Zhangjiang Hi-Tech Park Pudong New District, Shanghai China공시 • Mar 16MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2023 Results on Mar 27, 2024MicroPort CardioFlow Medtech Corporation announced that they will report fiscal year 2023 results on Mar 27, 2024공시 • Jan 08Microport Cardioflow Medtech Corporation Receives NMPA Approval for Registration Application of Anchorman LAAC SystemThe board of directors of the Company of MicroPort CardioFlow Medtech Corporation announced that, on January 5, 2024, MP CardioAdvent received the approval from the National Medical Products Administration of the People's Republic of China regarding the registration application for AnchorMan left atrial appendage closure system, the self-development product of MP CardioAdvent, which is also the only approved semi-closed type LAAC product in China so far. In addition, it completed the registration application of CE Mark in December 2023. AnchorMan LAAC System comprises a LAA closure and a delivery system, which is applicable for patients with nonvalvular atrial fibrillation with the CHA2DS2-VASC (a stroke risk assessment tool) score 2 and have contraindications in long-term oral anticoagulation therapy or still at risk of stroke after anticoagulation therapy. The major innovative designs of AnchorMan LAAC System include: the semi-closed structure formed by the 12 "3D folding" units and the frame combines the merits of an open and closed closure device, solving the clinical pain point that the access sheath of the traditional plug-in closure device must deep into the LAA, and achieving stable anchoring, the rounded and soft distal end could reduce damage to the LAA tissue; the dense NiTi alloy frame design allows very tight conformity to the anatomy of LAA and achieves better sealing performance; and two deployment models of advancement and unsheathe are available to provide more options for physicians. In addition, AnchorMan LAAC System is available in six closure device diameters ranging from 20 mm to 35 mm for a larger patient population. The NMPA registration approval of the AnchorMan LAAC System enables the Group to expand its business from heart valves to a new segment in the structural heart disease field with large patient population and fast growth rate, which will further expand the Company's revenue stream and enhance its comprehensive competitiveness.공시 • Oct 26MicroPort CardioFlow Medtech Corporation Completes Clinical Implantation Cases in EuropeThe board of directors of MicroPort CardioFlow Medtech Corporation announced that the Group's self-developed second-generation transcatheter aortic heart valve implantation ("TAVI") product, VitaFlow Liberty transcatheter aortic valve implantation system, has recently completed seven pre-market clinical implantation cases in Denmark and Ireland. All patients recovered well after the procedures. VitaFlow Liberty is the only self-developed TAVI product in China to conduct clinical trials in Europe, and is expected to become the first Chinese TAVI product to receive CE mark. As the world's first and only motorized retrievable TAVI system, after its registration approval by the China National Medical Products Administration in August 2021, VitaFlow Liberty has been successfully registered in Argentina, Colombia, Thailand and Russia and progressed its CE mark registration in good order. In its nearly 200 cases of overseas commercial applications, VitaFlow Liberty received high praises from overseas physicians for its excellent release stability, precise positioning, optimized perivalvular leakage prevention and hemodynamic performance. The successful advancement of VitaFlow Liberty's pre-market clinical trial will lay a solid foundation for its launch in markets recognizing the CE mark. The Group looks forward to the early approval for the CE mark registration of VitaFlow Liberty and its rapid subsequent commercialization in Europe to bring high quality and universally-accessible solutions to more TAVI patients around the world.공시 • Oct 17MicroPort CardioFlow Medtech Corporation Announces First Two Clinical Applications of Third-Generation TAVI ProductMicroPort CardioFlow Medtech Corporation announced that the third-generation transcatheter aortic heart valve implantation product independently developed by the Group ("Third-Generation TAVI Product") which is equipped with an upgraded retrievable steerable delivery system was successfully applied by the heart teams of Fuwai Hospital of the Chinese Academy of Medical Sciences and Shanxi Provincial Hospital of Cardiovascular Diseases to treat two patients with severe aortic stenosis. The patients are now recovering well with significant relief of related symptoms. The successful first-in-man applications of Third-Generation TAVI Product marked its entry into the clinical application phase and further enriched TAVI product offering to increase competitiveness. Originated from the Group's deep understanding of clinical needs and pain points, self-developed Third-Generation TAVI Product is an iteration of VitaFlow Liberty®, second-generation TAVI product which is now widely used in TAVI procedures. The delivery system of this product is upgraded with a highly innovative steerable function, which is designed to help cross the aortic arch and the native valve, facilitate the delivery process to achieve less tissue damage, enhance valve coaxiality during pre-positioning and release, make it easier to anchor in the appropriate position, further reduce the maneuver difficulty and increase positioning accuracy, thus improving the procedure success rate and enhancing the therapeutic effects. The unique spatial curvature is more in line with the human heart structure and is suitable for a variety of challenging anatomies. Meanwhile, the limit switch on the handle of the delivery system helps physicians to reduce the rate of intraoperative mishandling and further optimizes the procedure process. The first two successful clinical applications of the Third-Generation TAVI Product is another important milestone of the Group's comprehensive deployment in the field of structural heart disease, and a manifestation of solid technical reserves and innovative research & development capabilities in the field of structural heart diseases. The product impresses physicians with its excellent ease-of-use, more accurate positioning and improved procedure efficiency. look forward to the launch of the Third-Generation TAVI Product as soon as possible to treat more patients with aortic valve disease.공시 • Aug 30+ 2 more updatesMicroPort Cardioflow Medtech Corporation Announces Executive ChangesMicroPort CardioFlow Medtech Corporation announced that with effect from August 29, 2023: Mr. Chen Guoming has resigned as general manager of MP CardioFlow and re-designated from an executive Director to a non-executive Director, and has been appointed as the Chairman, the chairman of Nomination Committee, a member of Remuneration Committee, an Authorized Representative and the chairman of MP CardioFlow; and Mr. Jeffrey R Lindstrom has been appointed as the general manager of MP CardioFlow. Mr. Chen, aged 38, joined the Group as a vice president on September 1, 2016 and was mainly responsible for research and development ("R&D") since then and participating in the management and strategic development of Group. He served as an executive Director, President and director and general manager of MP CardioFlow from September 29, 2020 to August 29, 2023. Mr. Chen focused on research and development, clinical application and supply chain management of devices in the field of valves for more than 10 years. Before joining the Company in September 2016, Mr. Chen joined the group of MicroPort Scientific Corporation in March 2010 and worked as senior R&D manager at Shanghai MicroPort Medical (Group) Co. Ltd. from March 2010 to August 2016. Mr. Chen obtained a bachelor's degree in engineering mechanics from Shanghai Jiao Tong University in China in June 2007 and a master's degree in mechatronics engineering from Shanghai Jiao Tong University in China in March 2010. He is also the inventor or a co-inventor of over 100 invention patents in China and overseas as of the date of this announcement. Mr. Lindstrom, aged 57, joined Group in January 2022 as the vice president (R&D) of Company. He has over 25 years R&D experience in the minimally invasive interventional medical device industry. Prior to joining the Group, he served as senior director of engineering in Edwards Lifesciences Corporation (New York Stock Exchange ticker symbol: EW) since 2012, where he was responsible for developing the R&D strategy, directing and managing the R&D activities, overseeing the full product development lifecycle, leading the development and commercialization of the electro-mechanical transcatheter heart valve system and leading the development and clinical evaluation of the embolic protection system. From 2008 to 2012, he served as R&D director of The Spectranetics Corporation. From 1998 to 2006, he served as R&D manager of Abbott Vascular (formerly known as Guidant Corporation). Mr. Lindstrom obtained his bachelor's degree in chemical engineering from Illinois Institute of Technology in the United States in 1996. He also obtained the certificate of general management from UCLA Anderson School of Management in the United States in 2016. He owns six patents relating to the cardiovascular medical devices.공시 • Aug 18MicroPort CardioFlow Medtech Corporation to Report First Half, 2023 Results on Aug 29, 2023MicroPort CardioFlow Medtech Corporation announced that they will report first half, 2023 results on Aug 29, 2023이익 및 매출 성장 예측OTCPK:MROP.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202677712416N/A212/31/2025573-47-105-100212/31/2024454-162-70-4526/30/2024383-349-182-167N/A3/31/2024360-410-210-187N/A12/31/2023336-472-237-207N/A9/30/2023319-491-250-216N/A6/30/2023303-511-263-226N/A3/31/2023277-483-247-204N/A12/31/2022251-454-232-183N/A9/30/2022245-345-270-191N/A6/30/2022239-236-309-199N/A3/31/2022220-209-290-180N/A12/31/2021201-183-270-162N/A9/30/2021176-265N/AN/AN/A6/30/2021151-346N/AN/AN/A3/31/2021128-372N/AN/AN/A12/31/2020104-398-168-110N/A12/31/201922-145-191-143N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: MROP.F 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(2.6%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: MROP.F (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: MROP.F 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: MROP.F 의 수익(연간 24.7%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: MROP.F 의 수익(연간 24.7%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: MROP.F의 자본 수익률은 3년 후 1.7%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/12/22 03:05종가2024/09/25 00:00수익2024/06/30연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스MicroPort CardioFlow Medtech Corporation는 6명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Harry HeCGS Internationalnull nullChina International Capital Corporation LimitedBo YuChina International Capital Corporation Limited3명의 분석가 더 보기
공시 • Mar 31MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 04, 2026MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 04, 2026. Location: no.501 niudun road, pudong new district, shanghai, China
공시 • Mar 18MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2025 Results on Mar 30, 2026MicroPort CardioFlow Medtech Corporation announced that they will report fiscal year 2025 results on Mar 30, 2026
공시 • Aug 15MicroPort CardioFlow Medtech Corporation to Report First Half, 2025 Results on Aug 28, 2025MicroPort CardioFlow Medtech Corporation announced that they will report first half, 2025 results on Aug 28, 2025
공시 • Jun 27MicroPort CardioFlow Medtech Corporation Announces Board Changes, Effective June 27, 2025MicroPort CardioFlow Medtech Corporation announced that Dr. Ding Jiandong (Dr. Ding) retired as an independent non-executive Director with effect from the conclusion of the AGM and did not offer himself for re-election at the AGM as disclosed in the Circular. Accordingly, Dr. Ding ceased to act as a member of each of the audit committee (the Audit Committee) and nomination committee of the Company (the Nomination Committee) with effect from the conclusion of the AGM. Dr. Ding has confirmed that he has no disagreement with the Board and there is no matter relating to his retirement that needs to be brought to the attention of the Shareholders or the Stock Exchange. The Board announced that Dr. Hu Bingshan (Dr. Hu) has been appointed as an independent non-executive Director and a member of each of the Audit Committee and Nomination Committee, with effect from June 27, 2025 following the retirement of Dr. Ding. The biographical details of Dr. Hu are set out: Dr. Hu, aged 43, has successively served as associate professor and professor at the University of Shanghai for Science and Technology since November 2016. His main research field is rehabilitation and nursing robotics. From October 2010 to November 2016, Dr. Hu worked as a space robotics systems engineer at the Shanghai Aerospace System Engineering Institute in the China Aerospace Science and Technology Corporation. In 2015, he also served as a visiting scholar at the University of Hamburg in Germany. Dr. Hu serves as a committee member for the Sports Health and Industry Promotion Committee of China Association of Rehabilitation Medicine and other relevant academic organizations. He received the First Prize and the Second Prize of Science and Technology from the China Association of Rehabilitation Medicine in October 2023 and in September 2024, respectively. Dr. Hu has published more than 50 papers in internationally recognized journals or academic conferences. He is also an inventor or co-inventor of more than 70 Chinese and overseas patents. Dr. Hu received his bachelor's degree in electrical engineering and automation and his master's degree in power electronics and electric drives from Harbin University of Science and Technology in July 2003 and April 2006, respectively, and obtained his Ph.D. in mechatronic engineering from Shanghai Jiao Tong University in December 2010. Dr. Hu shall only hold office until the next annual general meeting of the Company and will be eligible for and subject to re-election at such meeting in accordance with the articles of association of the Company.
공시 • Mar 28MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 27, 2025MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 27, 2025. Location: no. 1661 zhangdong road, zhangjiang hi-tech park, pudong new district, shanghai China
공시 • Mar 17MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2024 Results on Mar 27, 2025MicroPort CardioFlow Medtech Corporation announced that they will report fiscal year 2024 results at 4:00 PM, China Standard Time on Mar 27, 2025
공시 • Aug 15MicroPort CardioFlow Medtech Corporation to Report First Half, 2024 Results on Aug 28, 2024MicroPort CardioFlow Medtech Corporation announced that they will report first half, 2024 results on Aug 28, 2024
공시 • Mar 29MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024MicroPort CardioFlow Medtech Corporation, Annual General Meeting, Jun 26, 2024. Location: No. 1661 Zhangdong Road, Zhangjiang Hi-Tech Park Pudong New District, Shanghai China
공시 • Mar 16MicroPort CardioFlow Medtech Corporation to Report Fiscal Year 2023 Results on Mar 27, 2024MicroPort CardioFlow Medtech Corporation announced that they will report fiscal year 2023 results on Mar 27, 2024
공시 • Jan 08Microport Cardioflow Medtech Corporation Receives NMPA Approval for Registration Application of Anchorman LAAC SystemThe board of directors of the Company of MicroPort CardioFlow Medtech Corporation announced that, on January 5, 2024, MP CardioAdvent received the approval from the National Medical Products Administration of the People's Republic of China regarding the registration application for AnchorMan left atrial appendage closure system, the self-development product of MP CardioAdvent, which is also the only approved semi-closed type LAAC product in China so far. In addition, it completed the registration application of CE Mark in December 2023. AnchorMan LAAC System comprises a LAA closure and a delivery system, which is applicable for patients with nonvalvular atrial fibrillation with the CHA2DS2-VASC (a stroke risk assessment tool) score 2 and have contraindications in long-term oral anticoagulation therapy or still at risk of stroke after anticoagulation therapy. The major innovative designs of AnchorMan LAAC System include: the semi-closed structure formed by the 12 "3D folding" units and the frame combines the merits of an open and closed closure device, solving the clinical pain point that the access sheath of the traditional plug-in closure device must deep into the LAA, and achieving stable anchoring, the rounded and soft distal end could reduce damage to the LAA tissue; the dense NiTi alloy frame design allows very tight conformity to the anatomy of LAA and achieves better sealing performance; and two deployment models of advancement and unsheathe are available to provide more options for physicians. In addition, AnchorMan LAAC System is available in six closure device diameters ranging from 20 mm to 35 mm for a larger patient population. The NMPA registration approval of the AnchorMan LAAC System enables the Group to expand its business from heart valves to a new segment in the structural heart disease field with large patient population and fast growth rate, which will further expand the Company's revenue stream and enhance its comprehensive competitiveness.
공시 • Oct 26MicroPort CardioFlow Medtech Corporation Completes Clinical Implantation Cases in EuropeThe board of directors of MicroPort CardioFlow Medtech Corporation announced that the Group's self-developed second-generation transcatheter aortic heart valve implantation ("TAVI") product, VitaFlow Liberty transcatheter aortic valve implantation system, has recently completed seven pre-market clinical implantation cases in Denmark and Ireland. All patients recovered well after the procedures. VitaFlow Liberty is the only self-developed TAVI product in China to conduct clinical trials in Europe, and is expected to become the first Chinese TAVI product to receive CE mark. As the world's first and only motorized retrievable TAVI system, after its registration approval by the China National Medical Products Administration in August 2021, VitaFlow Liberty has been successfully registered in Argentina, Colombia, Thailand and Russia and progressed its CE mark registration in good order. In its nearly 200 cases of overseas commercial applications, VitaFlow Liberty received high praises from overseas physicians for its excellent release stability, precise positioning, optimized perivalvular leakage prevention and hemodynamic performance. The successful advancement of VitaFlow Liberty's pre-market clinical trial will lay a solid foundation for its launch in markets recognizing the CE mark. The Group looks forward to the early approval for the CE mark registration of VitaFlow Liberty and its rapid subsequent commercialization in Europe to bring high quality and universally-accessible solutions to more TAVI patients around the world.
공시 • Oct 17MicroPort CardioFlow Medtech Corporation Announces First Two Clinical Applications of Third-Generation TAVI ProductMicroPort CardioFlow Medtech Corporation announced that the third-generation transcatheter aortic heart valve implantation product independently developed by the Group ("Third-Generation TAVI Product") which is equipped with an upgraded retrievable steerable delivery system was successfully applied by the heart teams of Fuwai Hospital of the Chinese Academy of Medical Sciences and Shanxi Provincial Hospital of Cardiovascular Diseases to treat two patients with severe aortic stenosis. The patients are now recovering well with significant relief of related symptoms. The successful first-in-man applications of Third-Generation TAVI Product marked its entry into the clinical application phase and further enriched TAVI product offering to increase competitiveness. Originated from the Group's deep understanding of clinical needs and pain points, self-developed Third-Generation TAVI Product is an iteration of VitaFlow Liberty®, second-generation TAVI product which is now widely used in TAVI procedures. The delivery system of this product is upgraded with a highly innovative steerable function, which is designed to help cross the aortic arch and the native valve, facilitate the delivery process to achieve less tissue damage, enhance valve coaxiality during pre-positioning and release, make it easier to anchor in the appropriate position, further reduce the maneuver difficulty and increase positioning accuracy, thus improving the procedure success rate and enhancing the therapeutic effects. The unique spatial curvature is more in line with the human heart structure and is suitable for a variety of challenging anatomies. Meanwhile, the limit switch on the handle of the delivery system helps physicians to reduce the rate of intraoperative mishandling and further optimizes the procedure process. The first two successful clinical applications of the Third-Generation TAVI Product is another important milestone of the Group's comprehensive deployment in the field of structural heart disease, and a manifestation of solid technical reserves and innovative research & development capabilities in the field of structural heart diseases. The product impresses physicians with its excellent ease-of-use, more accurate positioning and improved procedure efficiency. look forward to the launch of the Third-Generation TAVI Product as soon as possible to treat more patients with aortic valve disease.
공시 • Aug 30+ 2 more updatesMicroPort Cardioflow Medtech Corporation Announces Executive ChangesMicroPort CardioFlow Medtech Corporation announced that with effect from August 29, 2023: Mr. Chen Guoming has resigned as general manager of MP CardioFlow and re-designated from an executive Director to a non-executive Director, and has been appointed as the Chairman, the chairman of Nomination Committee, a member of Remuneration Committee, an Authorized Representative and the chairman of MP CardioFlow; and Mr. Jeffrey R Lindstrom has been appointed as the general manager of MP CardioFlow. Mr. Chen, aged 38, joined the Group as a vice president on September 1, 2016 and was mainly responsible for research and development ("R&D") since then and participating in the management and strategic development of Group. He served as an executive Director, President and director and general manager of MP CardioFlow from September 29, 2020 to August 29, 2023. Mr. Chen focused on research and development, clinical application and supply chain management of devices in the field of valves for more than 10 years. Before joining the Company in September 2016, Mr. Chen joined the group of MicroPort Scientific Corporation in March 2010 and worked as senior R&D manager at Shanghai MicroPort Medical (Group) Co. Ltd. from March 2010 to August 2016. Mr. Chen obtained a bachelor's degree in engineering mechanics from Shanghai Jiao Tong University in China in June 2007 and a master's degree in mechatronics engineering from Shanghai Jiao Tong University in China in March 2010. He is also the inventor or a co-inventor of over 100 invention patents in China and overseas as of the date of this announcement. Mr. Lindstrom, aged 57, joined Group in January 2022 as the vice president (R&D) of Company. He has over 25 years R&D experience in the minimally invasive interventional medical device industry. Prior to joining the Group, he served as senior director of engineering in Edwards Lifesciences Corporation (New York Stock Exchange ticker symbol: EW) since 2012, where he was responsible for developing the R&D strategy, directing and managing the R&D activities, overseeing the full product development lifecycle, leading the development and commercialization of the electro-mechanical transcatheter heart valve system and leading the development and clinical evaluation of the embolic protection system. From 2008 to 2012, he served as R&D director of The Spectranetics Corporation. From 1998 to 2006, he served as R&D manager of Abbott Vascular (formerly known as Guidant Corporation). Mr. Lindstrom obtained his bachelor's degree in chemical engineering from Illinois Institute of Technology in the United States in 1996. He also obtained the certificate of general management from UCLA Anderson School of Management in the United States in 2016. He owns six patents relating to the cardiovascular medical devices.
공시 • Aug 18MicroPort CardioFlow Medtech Corporation to Report First Half, 2023 Results on Aug 29, 2023MicroPort CardioFlow Medtech Corporation announced that they will report first half, 2023 results on Aug 29, 2023